El fibrosarcoma infantil (IFS) se define por la fusión ETV6-NTRK3 (>90%). Larotrectinib tiene...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-NTRK-FUSION-IFS |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-IFS |
| Fuentes | SRC-CIVIC SRC-FDA-CDS-2026 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-NTRK-FUSION |
|---|---|
| Variante | fusión ETV6-NTRK3 (lesión definida) |
| Enfermedad | DIS-IFS |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | larotrectinib monotherapy (1L for unresectable / metastatic IFS — chemotherapy-sparing), entrectinib monotherapy |
| Monoterapia contraindicada | VAC chemotherapy (vincristine/actinomycin/cyclophosphamide) as 1L when NTRK-TKI available — no longer standard given larotrectinib tolerability and efficacy |
| Resumen de las pruebas | Infantile fibrosarcoma (IFS) is defined by ETV6-NTRK3 fusion (>90%). Larotrectinib has transformative activity (SCOUT pediatric trial, Laetsch Lancet Oncol 2018 — ORR 93% in IFS), enabling organ-sparing surgery and avoiding mutilating resection or intensive chemotherapy. Tumor-agnostic FDA approval since 2018; SCOUT data drove pediatric label. |
Notas
ESCAT IA. OncoKB Level 1. IFS is the prototype tumor for the paradigm shift from cytotoxic to targeted therapy in pediatric oncology. Prior standard (VAC chemotherapy) achieved ~70% response but with substantial toxicity. Larotrectinib enables less mutilating surgery in localized IFS. Source-gap: SRC-NCCN-PEDIATRIC-SARCOMA / SRC-SCOUT not yet ingested.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.